Amazing News.......UK teenager wins battle to have body cryogenically frozen

A British teenager who died of cancer has been cryogenically frozen in the United States after winning a court case before her death.

The girl -- who can't be identified and is referred to only as "JS" -- suffered from a rare form of cancer and expressed a hope to be brought back to life and cured in the future.

She died on October 17 but details of the case at London's High Court were not allowed to be made public until now.

In his judgment, obtained by CNN, Mr. Justice Peter Jackson said the girl had expressed her desire to be cryogenically frozen.

She wrote: "I have been asked to explain why I want this unusual thing done. I'm only 14 years old and I don't want to die, but I know I am going to. I think being cryo-preserved gives me a chance to be cured and woken up, even in hundreds of years' time. I don't want to be buried underground.

"I want to live and live longer and I think that in the future they might find a cure for my cancer and wake me up. I want to have this chance. This is my wish."

Staying active with joint pain...

It's important to keep joints moving, even if you're dealing with pain from arthritis or an overuse injury. Try these joint-friendly options for physical activity: an elliptical trainer; a stationary bike (recumbent or upright); tai chi; swimming, water aerobics, or water walking; a rowing machine; short walks throughout the day, instead of a long walk.

FDA Approves Lartruvo

Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS).
Lartruvo was granted accelerated approval for adults with a histologic subtype of STS for which an anthracycline-containing regimen is appropriate, and which cannot be cured with radiotherapy or surgery. Approval was based on safety and efficacy data from the Phase 2 JGDG trial of 133 patients. Patients treated

FDA Approves Zinplava

The U.S. Food and Drug Administration (FDA) has approved Zinplava (bezlotoxumab), a monoclonal antibody indicated to reduce recurrence of Clostridium difficile infection (CDI) in adults who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.

Zinplava is a prescription medicine used to help decrease the risk of C-diff from coming back in people 18 years of age or older who are taking an antibiotic for C-diff and who have a high risk of C-diff coming back.
C-diff is a bacterial infection